Yusuke Watanabe
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Aims Residual mitral regurgitation (MR) after mitral transcatheter edge-to-edge repair (M-TEER) is associated with adverse prognosis. However, the long-term clinical impact of MR persistence or progression has not been well stratified. We aimed to evaluate the proportion, clinical benefits, and prognostic value of maintaining mild MR one year after M-TEER. Methods and Results This multicenter registry-based analysis included 1,865 patients who achieved mild MR at discharge following M-TEER. At one year, patients were classified as having stable MR (≤ mild) or worsening MR (≥ moderate). The frequency of left atrial (LA) and left ventricular (LV) reverse remodeling and tricuspid regurgitation (TR) improvement were assessed from baseline to one year. Clinical endpoints—including all-cause mortality and heart failure hospitalization—were evaluated beyond one year after M-TEER up to two years. Worsening MR occurred in 28.4% of patients. Compared with the worsening MR group, the stable MR group demonstrated significantly more frequent LA and LV reverse remodeling (38.4% vs. 28.1%, and 44.7% vs. 31.1%, respectively; both p<0.001). Improvement in TR (≥ grade 1) was also more prevalent in the stable MR group (32.4% vs. 20.6%, p<0.001). Worsening MR was independently associated with increased risk of adverse clinical outcomes (hazard ratio: 2.02; 95% confidence interval: 1.26–3.23; p=0.003). Conclusions Maintaining MR within mild at one-year post-M-TEER is associated with favorable cardiac reverse remodeling and improved clinical prognosis. These findings underscore the importance of long-term MR surveillance and its implications for outcome optimization following M-TEER.
Year:
2026
Aims In patients with ventricular functional mitral regurgitation (VFMR) undergoing transcatheter edge-to-edge repair (M-TEER), the prognostic significance of the ratio between mitral regurgitant volume and left atrial volume (LAV) remains unclear. This ratio may reflect the proportional or disproportionate burden of regurgitation on the left atrium. To address this gap, we aimed to investigate the association between the regurgitant volume (RVol)/LAV ratio and clinical outcomes in patients with VFMR, using data from a multicentre prospective registry. Methods and results We calculated the RVol/LAV ratio from baseline transthoracic echocardiograms. The median value of the RVol/LAV ratio was 0.40. A total of 1830 patients who underwent M-TEER were allocated into two groups: the low RVol/LAV (RVol/LAV ratio <0.40) and high RVol/LAV (RVol/LAV ratio ≥0.40) groups. The primary endpoint was heart failure hospitalization. Eight hundred eighty-eight and 942 patients were included into the low RVol/LAV ratio and high RVol/LAV ratio groups, respectively. The median follow-up period was 508 days. At 3 years after repair, 215 (37.6%) and 187 (32.1%) patients in the low RVol/LAV and high RVol/LAV groups, respectively, were hospitalized for heart failure. The patients in the low RVol/LAV group demonstrated a significantly higher risk of heart failure hospitalization than did those in the high RVol/LAV group (hazards ratio, 1.25; 95% confidence interval, 1.03–1.52; P = 0.022). Furthermore, using multivariable Cox regression analysis, the low RVol/LAV was an independent predictor of the primary endpoint. Conclusion The RVol/LAV ratio might serve as a valuable metric for improving risk stratification in patients with VFMR. Clinical trials OCEAN Mitral registry (UMIN ID: UMIN000023653)
Year:
2025
Background Coaptation gap (CG) is one of the challenging anatomies of mitral transcatheter edge-to-edge repair (TEER), but its impact on patient outcomes is unclear. This study aimed to evaluate the impact of CG on procedural and clinical outcomes in patients with functional mitral regurgitation (MR). Methods Data from 2140 patients undergoing TEER for functional MR were analysed, focusing on the presence of CG, which is a missing leaflet coaptation between the anterior and posterior leaflets during systole. The primary outcome was a composite of death, heart failure hospitalisation and mitral valve reintervention. Results Of the 2140 patients, 219 (10%) had CG and 1921 (90%) did not, as assessed by baseline transoesophageal echocardiography. In patients with CG, baseline MR grade and New York Heart Association (NYHA) functional class were more severe, and long/wide clip types were used more frequently. Post-TEER, patients with CG had significantly lower achievement of MR grade ≤2+ (93%) and ≤1+ (65%) compared with patients without CG (97%, p<0.01; 82%, p<0.01, respectively). NYHA functional class at 1 year was similar in both groups. The cumulative incidence of the primary outcome was comparable between CG and non-CG groups (51% vs 53% at 3 years, p=0.71). While residual MR grade 2+ was associated with the higher primary outcome incidence compared with ≤1+ in patients without CG (p<0.01), no significant difference was found in patients with CG (p=0.51). Conclusion CG was associated with less MR reduction but with no clear difference in adverse clinical outcomes after TEER. Similar outcomes between residual MR grade 2+ and ≤1+ in CG patients highlight the importance of procedural endpoint in anatomically challenging cases. Trial registration number UMIN000023653.
Year:
2025
Background The association of outcomes with initial clip selection has not been investigated in patients undergoing transcatheter edge‐to‐edge repair with the MitraClip G4. Methods We analyzed 2257 patients receiving the MitraClip G4 according to the initial clip type: short (NT/NTW) versus long (XT/XTW) and narrow (NT/XT) versus wide (NTW/XTW). We performed a propensity‐matched analysis of baseline anatomical features in patients with primary and secondary mitral regurgitation (MR). Results The proportions of the initial clip types were as follows: NT, 18.9%; NTW, 41.7%; XT, 5.1%; and XTW, 34.3%. The proportions of the MR severity ≤1+ at discharge and 1 year were not significantly different among the 4 clip types. The incidence of death or heart failure hospitalization was not significantly different between the initial long and short clip groups and between the initial wide and narrow clip groups. After propensity matching, in patients with primary MR, long clips were significantly associated with a greater MR reduction (2.87±0.89 versus 2.62±0.99, P =0.04) and a higher proportion of the MR severity ≤1+ at 1 year (68.2% versus 48.6%, P =0.04) than short clips. In patients with secondary MR, long or wide clips had a similar MR severity at discharge and 1 year as short or narrow clips. Conclusions Residual MR severity and outcomes were not different regardless of the initial clip type, indicating the optimal clip selection in the real‐world settings with the MitraClip G4. In patients with primary MR, greater and more durable MR reduction may be expected by using the initial long clips. Registration URL: https://www.umin.ac.jp/ctr/ ; Unique identifier: UMIN‐ID: UMIN000023653.
Year:
2025
Background Low serum albumin levels indicate frailty and are strong predictors of poor prognosis after mitral transcatheter edge‐to‐edge repair (M‐TEER); however, albumin levels are expected to improve in response to treatment for mitral regurgitation. No reports have elucidated the clinical effects of albumin changes after M‐TEER. Thus, we aimed to explore the association between early albumin changes and clinical outcomes after M‐TEER and to identify the associated factors. Methods Data from 2695 patients enrolled in a Japanese multicenter registry whose serum albumin levels were measured before and 1 month after undergoing M‐TEER were retrospectively reviewed. Changes in albumin (Δ‐albumin) were calculated and divided into 2 groups, namely improved albumin (Δ‐albumin >0) and worsening albumin (Δ‐albumin ≤0) groups. The incidence, predictors, and clinical outcomes associated with early albumin changes were investigated. Results After M‐TEER, albumin levels improved in 56.1% of the patients (n=1512). The independent predictors of worsening Δ‐albumin comprised old age, acute procedure success not achieved, higher Clinical Frailty Scale, higher hemoglobin, impaired renal function, and preprocedural higher albumin levels (all P <0.05). Improved Δ‐albumin was independently associated with reduced all‐cause mortality after M‐TEER (hazard ratio [HR], 0.62 [95% CI, 0.52–0.75], P <0.001). Additionally, improved Δ‐albumin was associated with a lower competing risk of heart failure hospitalization (HR, 0.78 [95% CI, 0.64–0.94], P =0.01). Conclusions Early improvement in Δ‐albumin may serve as a measure of procedural benefits and a surrogate marker for predicting clinical outcomes after M‐TEER.
Year:
2025
Aims Left ventricular outflow tract (LVOT) obstruction is a key feature of hypertrophic obstructive cardiomyopathy (HOCM), whereas patent foramen ovale (PFO) obstruction is associated with cryptogenic stroke and other conditions. The Valsalva manoeuvre (VM) is a standard technique for diagnosing these conditions; however, its inconsistent execution can limit diagnostic accuracy. We aimed to evaluate the party balloon inflation manoeuvre (PBIM) as an alternative to VM for diagnosing HOCM and PFO by comparing their haemodynamic effects. Methods and results In this single-centre pilot study, we conducted in vitro and in vivo experiments. The pressure characteristics of the two balloon sizes were measured in the in vitro experiment. In the in vivo study, we assessed haemodynamic changes in 25 healthy volunteers using transthoracic echocardiography. The endpoints included the left ventricular diastolic dimension (LVDd) for HOCM and the right ventricular inflow velocity-time integral (RV inflow-VTI) for PFO. PBIM significantly reduced LVDd compared with VM, indicating greater LVOT obstruction provocation (P < 0.01). The RV inflow-VTI was also significantly higher with PBIM, suggesting increased venous return and enhanced right-to-left shunting (P < 0.01). The heart rate and perceived exertion scores were higher with the PBIM, reflecting a greater physiological load. Conclusion PBIM is a simple, effective, and reliable alternative to VM for diagnosing HOCM and PFO, offering clear visual feedback and improved diagnostic performance. Further research in patient populations is required to confirm these findings. Trial registration number: UMIN000054423. (https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000062098&type=summary&language=J).
Year:
2025
BACKGROUND: The extent of cardiac damage and its association with clinical outcomes in patients undergoing transcatheter edge-to-edge repair (TEER) for degenerative mitral regurgitation remains unclear. This study was aimed to investigate cardiac damage in patients with degenerative mitral regurgitation treated with TEER and its association with outcomes. METHODS: We analyzed patients with degenerative mitral regurgitation treated with TEER in the Optimized Catheter Valvular Intervention-Mitral registry, which is a prospective, multicenter observational data collection in Japan. The study subjects were classified according to the extent of cardiac damage at baseline: no extravalvular cardiac damage (stage 0), mild left ventricular or left atrial damage (stage 1), moderate left ventricular or left atrial damage (stage 2), or right heart damage (stage 3). Two-year mortality after TEER was compared using Kaplan-Meier analysis. RESULTS: Out of 579 study participants, 8 (1.4%) were classified as stage 0, 76 (13.1%) as stage 1, 319 (55.1%) as stage 2, and 176 (30.4%) as stage 3. Two-year survival was 100% in stage 0, 89.5% in stage 1, 78.9% in stage 2, and 75.3% in stage 3 ( P =0.013). Compared with stage 0 to 1, stage 2 (hazard ratio, 3.34 [95% CI, 1.03–10.81]; P =0.044) and stage 3 (hazard ratio, 4.51 [95% CI, 1.37–14.85]; P =0.013) were associated with increased risk of 2-year mortality after TEER. Significant reductions in heart failure rehospitalization rate and New York Heart Association functional scale were observed following TEER (both, P <0.001), irrespective of the stage of cardiac damage. CONCLUSIONS: Advanced cardiac damage is associated with an increased risk of mortality in patients undergoing TEER for degenerative mitral regurgitation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: UMIN000023653.
Year:
2024
BACKGROUND: A small mitral valve area (MVA) is one of the challenging anatomies for transcatheter edge-to-edge repair (TEER) for mitral regurgitation, but the relationship between baseline MVA and clinical outcomes remains unknown. This study aimed to evaluate the association of baseline MVA with procedural and clinical outcomes in patients undergoing TEER with MitraClip from the OCEAN-Mitral registry (Optimized Catheter Valvular Intervention-Mitral). METHODS: A total of 1768 patients undergoing TEER were divided into 3 groups according to baseline MVA: group 1: <4.0 cm 2 , n=358; group 2: 4.0–5.0 cm 2 , n=493; and group 3: ≥5.0 cm 2 , n=917. The primary end point was a composite of all-cause death and heart failure hospitalization within 2 years of TEER and compared between the 3 groups. RESULTS: Patients with smaller MVA had significantly fewer clips implanted and higher postprocedural transmitral mean pressure gradient. There was no significant difference in the acute procedural success rate and postprocedural mitral regurgitation severity between the 3 groups. The incidence of the primary end point was similar in group 1 compared with groups 2 and 3 (35.2% versus 34.5% versus 34.0%; P =0.96) and was also similar in patients with MVA <3.5 cm 2 and those with MVA 3.5 to 4.0 cm 2 . The adjusted risk of MVA <4.0 cm 2 relative to MVA of 4.0 to 5.0 cm 2 and MVA ≥5 cm 2 for the primary end point remained insignificant (hazard ratio, 1.06 [95% CI, 0.79–1.41]; P =0.68; hazard ratio, 0.99 [95% CI, 0.75–1.31]; P =0.96, respectively). At 1 year, no significant difference in the proportion of residual mitral regurgitation 3+/4+ was observed between the 3 groups (7.2% versus 4.4% versus 6.5%; P =0.49). CONCLUSIONS: In patients undergoing TEER, a small MVA <4.0 cm 2 may limit the number of clips implanted and increase the transmitral pressure gradient after TEER, but baseline MVA was not associated with mitral regurgitation reduction and clinical outcomes. REGISTRATION: URL: https://center6.umin.ac.jp/cgiope n-bin/ctr/ctr_view.cgi?recptno=R000027188 ; Unique identifier: UMIN000023653.
Year:
2024
Background The Direct Oral Anticoagulant (DOAC) Score can predict bleeding risk in patients with atrial fibrillation taking DOACs; however, it lacks external validation. Therefore, this study aimed to assess the association between the DOAC Score and bleeding events in patients with atrial fibrillation who underwent transcatheter aortic valve replacement. Methods and Results This retrospective multicenter cohort study included patients with atrial fibrillation who underwent transcatheter aortic valve replacement, as registered in a Japanese multicenter registry. The primary end point was the incidence of bleeding. Patients were categorized based on their DOAC Score: low and moderate‐ (≤7 points), high‐ (8–9 points), and very high‐risk (≥10 points) groups. Among 1230 patients (mean age 84.6±5.1 years; 457 men), 465 (37.8%) received a vitamin K antagonist, and the remaining patients received DOACs. The low and moderate‐, high‐, and very high‐risk groups included 380 (30.1%), 497 (40.4%), and 353 patients (28.7%), respectively. The 3‐year cumulative incidence of all bleeding events was significantly different among the 3 groups (low and moderate risk: 6.6%, high risk: 6.9%, and very high risk: 14.0%; P <0.01). Multivariable Cox regression analysis revealed that significant increments in the DOAC Score were associated with a risk of all bleeding events at 3 years in the overall cohort (hazard ratio [HR], 1.22 [95% CI, 1.08–1.38]; P <0.01), in the DOAC cohort (HR, 1.20 [95% CI, 1.01–1.42]; P =0.04), and in the vitamin K antagonist cohort (HR, 1.25 [95% CI, 1.04–1.50]; P =0.02). Conclusions The DOAC Score was significantly associated with bleeding events in patients with atrial fibrillation after transcatheter aortic valve replacement, aiding in clinical decision‐making for anticoagulant management. Registration URL: https://center6.umin.ac.jp/cgi‐open‐bin/ctr_e/ctr_view.cgi?recptno=R000023585 ; Unique identifier: UMIN000020423.
Year:
2024
Background The Clinical Frailty Scale (CFS) is a useful frailty marker for predicting clinical outcomes in patients undergoing invasive therapy. However, the clinical impact of CFS after transcatheter edge‐to‐edge repair in patients with mitral regurgitation (MR) remains unclear. This study aimed to elucidate the association between the baseline frail status defined by the CFS and clinical outcomes with or without postprocedural MR ≥2+ (post‐MR ≥2+) after transcatheter edge‐to‐edge repair. Methods and Results Based on a Japanese multicenter registry (OCEAN [Optimized Catheter Valvular Intervention]‐Mitral), data from 2078 patients with MR who underwent transcatheter edge‐to‐edge repair were analyzed. The patients were classified into 5 groups: CFS 1 to 3, 4, 5, 6, and ≥7. The procedural and clinical outcomes and post‐MR ≥2+ were compared among the groups. All‐cause mortality for up to 2 years was explored using Cox proportional hazards regression analysis. Although the rates of acute procedural success and post‐MR ≥2+ were similar, all‐cause mortality at 2 years was significantly increased across the 5 CFS categories (15.5%, 23.8%, 27.7%, 34.6%, and 48.8%, respectively, P <0.001). The incremental CFS categories and post‐MR ≥2+ were independent predictive risk factors of all‐cause mortality (all P <0.05). Among the patients with 5 CFS categories, the incidence of all‐cause mortality was higher in those with post‐MR ≥2+ than in those without (all P <0.05). Conclusions Although prognosis was poor in patients with higher CFS grade after transcatheter edge‐to‐edge repair, minimizing modifiable factors of residual MR is warranted to improve the clinical outcomes. Registration Information URL: https://center6.umin.ac.jp/cgi‐open‐bin/ctr/ctr_view.cgi?recptno=R000027188 ; Unique identifier: UMIN000023653.
Year:
2024
Year:
2024
Year:
2023
Collaborators (3)
Kentaro Hayashida
Keio University School of Medicine
Gaku Nakazawa
Kindai University Hospital
Hiroshi Ueno
University of Toyama
Make your next move.
Prepare your application
Review drafts before you send them.